Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 27.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: to determineprimarychroniconsetdetermine the
  Phrases that lowered it: nasalefficacyasthmaand safetyevaluation of
• Phase: 2 (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 9.5% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 93.0% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 21 (lowers risk) · Sponsor's track record
• Maximum age: 65 (lowers risk) · Who can join
• Sponsor's past trials: 11 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir NCT00799760 · started 2008 · scored riskier than 39% of active trials terminated
• A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection NCT00979667 · started 2009 · scored riskier than 35% of active trials terminated
• TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients NCT00867139 · started 2009 · scored riskier than 17% of active trials completed
• Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza NCT05095545 · started 2017 · scored riskier than 17% of active trials completed
• Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment NCT01146535 · started 2011 · scored riskier than 12% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.